FKB238: A Bevacizumab Biosimilar

<p><b>Declarations</b></p> <p><b><br></b></p><p><b>Funding</b> The preparation of this review was not supported by any external funding.</p> <p><b><br></b></p><p><b>Authorship and Conflict of interest</b> Yahiya Y. Syed is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.</p> <p> </p> <p><b><br></b></p><p><b>Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability</b> not applicable<b></b></p> <p> </p> <p><br></p><p>Additional information about this Adis Drug Review can be found <a href="https://www.springer.com/gp/adis/products-services/adis-journals-newsletters/adis-drug-reviews">here</a></p> <p> </p> <p><b><br></b></p><p><b>Abstract</b></p> <p>FKB238 is a biosimilar of bevacizumab (a monoclonal antibody against vascular endothelial growth factor) approved for use in the same types of cancer as reference bevacizumab. FKB238 has similar physicochemical and pharmacodynamic properties to those of reference bevacizumab and pharmacokinetic equivalence was shown in healthy volunteers and in patients with non-small cell lung cancer (NSCLC). FKB238 demonstrated equivalent clinical efficacy to reference bevacizumab in patients with advanced or recurrent nonsquamous NSCLC, with similar tolerability, safety and immunogenicity profiles.</p><p><br></p> <p> </p> <p>© Springer Nature Switzerland AG 2021</p>